Effects of GABA active steroids in the female brain with a focus on the premenstrual dysphoric disorder

Abstract

Premenstrual dysphoric disorder (PMDD) afflicts 3%-5% of women of childbearing age, and is characterised by recurrent negative mood symptoms (eg, irritability, depression, anxiety and emotional lability) during the luteal phase of the menstrual cycle. The aetiology of PMDD is unknown, although a temporal association with circulating ovarian steroids, in particular progesterone and its metabolite allopregnanolone, has been established during the luteal phase. Allopregnanolone is a positive modulator of the GABA A receptor: it is sedative in high concentrations but may precipitate paradoxical adverse effects on mood at levels corresponding to luteal phase concentrations in susceptible women.Saccadic eye velocity (SEV) is a measure of GABA A receptor sensitivity; in experimental studies of healthy women, i.v. allopregnanolone decreases SEV. Women with PMDD display an altered sensitivity to an i.v. injection of allopregnanolone compared to healthy controls in this model. In functional magnetic resonance imaging (fMRI) studies, women with PMDD react differently to emotional stimuli in contrast to controls. A consistent finding in PMDD patients is increased amygdala reactivity during the luteal phase. Postmortem studies in humans have revealed that allopregnanolone concentrations vary across different brain regions, although mean levels in the brain also reflect variations in peripheral serum concentrations. The amygdala processes emotions such as anxiety and aggression. This is interesting because allopregnanolone is detected at high concentrations within the region into which marked increases in blood flow are measured with fMRI following progesterone/allopregnanolone administration. Allopregnanolone effects are antagonised by its isomer isoallopregnanolone (UC1010), which significantly reduces negative mood symptoms in women with PMDD when administered s.c. in the premenstrual phase. This was shown in a randomised, placebo-controlled clinical trial in which the primary outcome was change in symptom scoring on the Daily Rating of Severity of Problems (DRSP): the treatment reduced negative mood scores (P < .005), as well as total DRSP scores (P < .01), compared to placebo in women with PMDD. In conclusion, the underlying studies of this review provide evidence that allopregnanolone is the provoking factor behind the negative mood symptoms in PMDD and that isoallopregnanolone could ameliorate the symptoms as a result of its ability to antagonise the allopregnanolone effect on the GABA A receptor. K E Y W O R D SGABA, neuroactive steroids, premenstrual dysphoric disorder

An updated review on pathophysiology and management of burning mouth syndrome with endocrinological, psychological and neuropathic perspectives

“…Neuroprotective steroids, especially progesterone metabolites, modulate gamma‐aminobutyric acid (GABA) A receptors . Substantial evidence suggests that some neuroprotective steroids are associated with mood disorders via GABA A receptors . Allopregnanolone exerts an anxiolytic effect by inducing positive allosteric modulation of the GABA A receptor and negative modulation of hypothalamic‐pituitary‐adrenal (HPA) axis activity .…”

Repetitive Skin Focused Disorders May Express a Functional Connectome

“…44 Seventy-seven percent of the patients in this series were female, suggesting that there may be gender differences in brain regions involved with emotion and perception ( Table 2). [45][46][47][48][49][50] The effect of oral contraceptives and menstrual cycle phase on fear, memory, and anxiety remain largely unknown. [51][52] Women approach medical care differently, being open to taking prescriptions while also showing interest in natural approaches that include supplements and self-directed care.…”

Trends in Research Related to Premenstrual Syndrome and Premenstrual Dysphoric Disorder: a Bibliometric Analysis

“…Progesterone and its metabolites (e.g., allopregnanolone) have been regarded as hot topics in scientific research on PMS/PMDD [26] [27]. Recent studies now provide strong evidence that allopregnanolone could ameliorate the symptoms as a result of its ability to antagonize the allopregnanolone effect on the GABAA receptor [28].…”